Compound 4f

oral, brain-penetrant, reversible MAGL inh.

in vivo PK/PD in CNS (0.3-10 mpk PO)

from HTS and SBDD

Journal of Medicinal Chemistry

Takeda, Fujisawa, Japan

The Takeda MAGL inhibitor, “compound 4f”, was selected by reviewer Joachim Rudolph. “MAGL (monoacylglycerol lipase) is implicated in neuroinflammation, and inhibitors of this enzyme are of interest as therapeutics in neurodegenerative…


 this content is exclusive to
Premium members

Unlock this content with a Premium membership to read it now.